Pelias Biomedizinische Entwicklungs AG

Leading the Combat of Hospital-Acquired Infections

Founded in October 2005, Pelias combines unique know-how and dedicated development expertise in the field of infectious diseases with advanced projects licensed from Chiron and Intercell. On the basis of a lead program that has successfully completed phase I and phase IIa trials, the Company expects to initiate pivotal studies within just 18 months after incorporation.

Pelias' programs include preventive and therapeutic vaccines as well as therapeutic antibodies. All of them target common pathogens causing serious or life-threatening infections frequently acquired during hospitalization. Over the last decade, such hospital-acquired infections have developed into one of the world's most pressing public health problems due to the emergence and dissemination of microbes that are resistant against available antibiotics. This development, together with a diminishing number of newly approved antibiotic classes, has created an urgent medical need in this field. Pelias programs carry the promise to deliver new, effective medicines that will prevent and help control the threat of hospital-acquired infections.